Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Cancer Metastatic: early-phase trial registry

5 of 10 indexed Cancer Metastatic trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 5 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Cancer Metastatic: 10 US clinical trials tracked, 5 recruiting.

Cancer Metastatic is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Loren Mell, MD, running 1 of these trials.

Enrollment posture brief

Registry condition cancer-metastatic

OPEN 5 | RECR 50% | LATE 1 | EARLY 5 | RANK #1724 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Acute Leukemia of Ambiguous 80%Cancer Metastatic (this)50%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Cancer Metastatic

Cancer Metastatic lists 5 open slots (50% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cancer Metastatic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cancer Metastatic is recruiting above its size-band peers.

    5 of 10 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Cancer Metastatic trials is spread across many organizations.

    Loren Mell, MD accounts for 1 of 10 trials (10%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cancer Metastatic enrolment sits around 120 participants.

    Median target enrolment is 120 among the 10 trials that report a genuine target (sentinel values excluded). 4 of those (40%) plan for fewer than 100 participants.

  4. Cancer Metastatic splits between interventional and observational designs.

    6 interventional and 4 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 23Phase 31

Open and recent trials

10 total, page 1 of 1

RECRUITING 50,000 participants

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio

NCT03452774

RECRUITING 500 participants

UNC Childhood, Adolescent, and Young Adult Cancer Cohort

UNC Lineberger Comprehensive Cancer Center

NCT05096923

RECRUITING 100 participants

IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pelvis Fractures

Massachusetts General Hospital

NCT04842266

RECRUITING Phase 1 78 participants

An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Shenzhen Ionova Life Sciences Co.

NCT04443088

RECRUITING Phase 1 72 participants

Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer

Valley Health System

NCT05232409

ACTIVE NOT RECRUITING Phase 3 387 participants

Lay Coach-Led Early Palliative Care for Underserved Advanced Cancer Caregivers: The Project ENABLE Cornerstone RCT

University of Alabama at Birmingham

NCT04318886

ACTIVE NOT RECRUITING Phase 2 126 participants

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

Loren Mell, MD

NCT03383094

ACTIVE NOT RECRUITING Phase 2 120 participants

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Aadi Bioscience

NCT05103358

ACTIVE NOT RECRUITING 80 participants

Digitally-Captured Step Counts for Evaluating Performance Status in Advanced Cancer Patients

Cedars-Sinai Medical Center

NCT03757182

COMPLETED Phase 2 7 participants

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

University of California, San Diego

NCT03993353

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 3 1

Named interventions

Most-linked intervention names on Cancer Metastatic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Pembrolizumab Drug
2 trials
ENABLE Cornerstone Behavioral
1 trials
Wearable activity monitor Other
1 trials
Clinical Trial Matching Other
1 trials
INV-1120 Drug
1 trials
Tadalafil Drug
1 trials
Zeaxanthin Plus Pembrolizumab Combination
1 trials
Zeaxanthin Biological
1 trials

US sites by state

Facility locations filed on Cancer Metastatic trials. A trial with sites in several states counts in each.

California 5 trials
Arizona 3 trials
Alabama 3 trials
Florida 2 trials
Texas 1 trials
Tennessee 1 trials
Ohio 1 trials
New Jersey 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cancer Metastatic page

10 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 5 Cancer Metastatic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Loren Mell, MD sponsors the most Cancer Metastatic trials on record, review their full trial history before evaluating a specific study. See Loren Mell, MD's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cancer Metastatic condition card totals 10 registered trials; most-linked intervention Pembrolizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.